TTK Healthcare Limited (TTKHLTCARE) AI Stock Analysis

• Market Cap: ₹16.55B
• Dividend Yield: 0.9%
• Average Volume (3M): 82.00
• Price to Earnings (P/E): 25.0
• Beta (1Y): 0.81
• Revenue Growth: 6.98%
• EPS Growth: -17.11%
• Country: IN
• Employees: 1,316
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 14.43
• Shares Outstanding: 14,130,333
• 10 Day Avg. Volume: 50
• 30 Day Avg. Volume: 82
• PEG Ratio: 0.68
• Price to Book (P/B): 1.57
• Price to Sales (P/S): 1.91
• P/FCF Ratio: -99.33
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 71 Outperform
• Price Target: ₹1,313.00 ▲(18.29% Upside)

TTK Healthcare Limited's overall stock score is driven by its strong financial stability and moderate technical indicators. While the company shows solid revenue growth and a healthy balance sheet, cash flow management issues and a fair valuation limit the score. The absence of recent earnings call insights and notable corporate events means these factors did not influence the score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates robust market demand and effective sales strategies, enhancing long-term business sustainability.

Balance Sheet Health

A strong balance sheet with low leverage provides financial stability and flexibility to invest in growth opportunities.

Product and Market Diversification

Diversified operations across multiple sectors reduce risk and allow the company to capitalize on various growth opportunities.

Negative Factors

Cash Flow Management

Ongoing cash flow challenges may hinder the company's ability to fund operations and growth initiatives, impacting long-term viability.

Declining EBITDA Margin

Decreasing margins may indicate rising costs or inefficiencies, which could erode profitability if not addressed.

Earnings Volatility

Negative EPS growth reflects earnings volatility, which can undermine investor confidence and limit capital raising potential.

TTK Healthcare Limited Business Overview & Revenue Model

Company Description

TTK Healthcare Limited (TTKHLTCARE) is an Indian healthcare company primarily engaged in the manufacturing and marketing of healthcare products. The company operates in various sectors, including pharmaceuticals, consumer healthcare, and medical devices. Its core products include a range of personal care products, medical supplies, and diagnostic devices, which cater to both domestic and international markets.

How the Company Makes Money

TTK Healthcare generates revenue through multiple streams, including the sale of pharmaceutical products, consumer healthcare items, and medical devices. The company’s revenue model is primarily based on direct sales to hospitals, pharmacies, and retail chains as well as distribution through various channels. Significant partnerships with healthcare institutions and collaborations with international pharmaceutical companies also contribute to its earnings. Additionally, the company invests in research and development to innovate and expand its product offerings, further enhancing its revenue potential.

TTK Healthcare Limited Financial Statement Overview

Summary

TTK Healthcare Limited exhibits solid financial performance with strong revenue growth and financial stability. The company has a robust balance sheet with low leverage and high equity ratio. However, challenges in cash flow management, such as negative free cash flow and operating cash flow, need to be addressed.

Income Statement

TTK Healthcare Limited has demonstrated a strong revenue growth trajectory, with a notable increase in total revenue from 2024 to 2025. The gross profit margin is robust, showcasing effective cost management. However, the declining EBITDA margin suggests potential increases in operational costs or inefficiencies.

Balance Sheet

The company maintains a healthy balance sheet with a low debt-to-equity ratio and a strong equity ratio, indicating financial stability and low leverage. The high ROE reflects efficient use of equity to generate profits.

Cash Flow

Cash flow analysis reveals challenges, with negative free cash flow and operating cash flow figures. Although there is an improvement in free cash flow growth year-on-year, the negative operating cash flow to net income ratio highlights ongoing cash management issues.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	8.20B	8.73B	7.48B	7.25B	5.99B	4.76B
Gross Profit	5.54B	5.04B	4.07B	3.77B	3.09B	1.38B
EBITDA	1.03B	1.06B	999.35M	796.81M	406.58M	373.52M
Net Income	630.81M	816.57M	628.42M	6.40B	415.88M	464.41M
Balance Sheet
Total Assets	0.00	12.81B	12.01B	11.70B	5.59B	4.94B
Cash, Cash Equivalents and Short-Term Investments	8.55B	8.55B	8.45B	8.47B	2.73B	2.27B
Total Debt	0.00	242.19M	228.11M	273.29M	222.13M	191.44M
Total Liabilities	-10.65B	2.16B	2.00B	2.17B	2.29B	2.00B
Stockholders Equity	10.65B	10.65B	10.01B	9.53B	3.30B	2.95B
Cash Flow
Free Cash Flow	0.00	-168.16M	-153.27M	-377.75M	385.02M	946.88M
Operating Cash Flow	0.00	-39.76M	-49.43M	-260.76M	449.96M	964.21M
Investing Cash Flow	0.00	201.03M	284.94M	329.59M	-305.47M	-772.39M
Financing Cash Flow	0.00	-180.81M	-219.11M	-124.26M	-51.77M	-171.56M

TTK Healthcare Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1110.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:TTKHLTCARE, the sentiment is Negative. The current price of 1110 is below the 20-day moving average (MA) of 1137.20, below the 50-day MA of 1155.20, and below the 200-day MA of 1200.54, indicating a bearish trend. The MACD of -13.72 indicates Positive momentum. The RSI at 41.80 is Neutral, neither overbought nor oversold. The STOCH value of 25.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:TTKHLTCARE.

TTK Healthcare Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMRUTANJAN	72 Outperform	₹20.01B	34.89	―	0.67%	7.36%	19.31%
TTKHLTCARE	71 Outperform	₹16.55B	24.97	―	0.90%	6.98%	-17.11%
SMSPHARMA	65 Neutral	₹24.95B	33.41	―	0.13%	11.91%	36.92%
VIMTALABS	64 Neutral	₹27.65B	35.10	―	0.16%	17.05%	56.84%
WINDLAS	62 Neutral	₹19.77B	30.04	―	0.73%	19.34%	9.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BAJAJHCARE	51 Neutral	₹13.44B	29.31	―	0.23%	13.04%	―